AR053235A1 - Derivados de tienopirimidinas para el tratamiento de enfermedades inflamatorias - Google Patents
Derivados de tienopirimidinas para el tratamiento de enfermedades inflamatoriasInfo
- Publication number
- AR053235A1 AR053235A1 ARP060101573A ARP060101573A AR053235A1 AR 053235 A1 AR053235 A1 AR 053235A1 AR P060101573 A ARP060101573 A AR P060101573A AR P060101573 A ARP060101573 A AR P060101573A AR 053235 A1 AR053235 A1 AR 053235A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkynyl
- alkenyl
- alkyl
- aryl
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D521/00—Heterocyclic compounds containing unspecified hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Compuesto de la formula (1) en los que: X es O, S, SO o SO2; R1 es H, alquilo C1-6-, alquenilo C2-6, alquinilo C2-6, arilo C6-10 o aril C6-10-alquileno C1-6, heteroarilo C5-10-alquileno C1-6; R2 es H o un radical eventualmente mono- polisustituido seleccionado del grupo compuesto por alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-10, mono- o bicíclico eventualmente puenteado una o varias veces, arilo C6-10, un anillo C3-10 heterocíclico aromático o no aromático, un anillo bicíclico y un arilo C6-10 condensado con un heterociclo C3-10; o NR1R2 significan juntos un anillo heterocíclico que está eventualmente sustituido con uno o varios radicales seleccionados de alquilo C1-4, alquenilo C2-6, alquinilo C2-6, alcanol C1- 6 lineal o ramificado y oxo; R3 un radical mono- o polisustituido seleccionado del grupo compuesto por un anillo C6-10 heterocíclico, cicloalquilo C3-7, aril C6-10-alquileno C1-6, heteroaril C5-10-alquileno C1-6, un anillo bicíclico condensado que eventualmente puede contener 1-4 heteroátomos seleccionados, de modo independiente entre sí, de N, O, S; o R3 significa fenilo eventualmente sustituido; o R3 significa un grupo COR3.7, COCH2R3.8, CONHR3.8 o SO2R3.8; en donde R3.7 es H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7 o un radical seleccionado del grupo compuesto por arilo C6-10, un anillo C3-10 heterocíclico y un anillo bicíclico que eventualmente está sustituido con uno o varios radicales seleccionados del grupo compuesto por alquilo C1-6, alquenilo C2-6, alquinilo C2-6, halogeno, NR3.8.1R3.8.1, arilo C6-10 y un anillo C3-10 heterocíclico; en donde R3.8.1 es H, alquilo C1-6, alquenilo C2-6 o alquinilo C2-6; R3.8.2 es H, alquilo C1-6, alquenilo C2-6 o alquinilo C2-6; R4 es H, alquilo C1-4, alquenilo C2-4,alquinilo C2-4 u oxo; R5 es H, alquilo C1-4, alquenilo C2-4, o alquinilo C2-4; R6 es H, alquilo C1-4, alquenilo C2-4, o alquinilo C2-4; R7 es H, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, arilo C6-10 u OH; R8 es H, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, arilo C6-10 u OH; o R7 y R8 forman juntos oxo, así como sus sales, diastereomeros, enantiomeros, racematos, hidratos o solvatos farmacologicamente tolerables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005019201A DE102005019201A1 (de) | 2006-04-19 | 2006-04-19 | Neue Verbindungen zur Behandlung von entzündlichen Erkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053235A1 true AR053235A1 (es) | 2007-04-25 |
Family
ID=36678631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101573A AR053235A1 (es) | 2006-04-19 | 2006-04-21 | Derivados de tienopirimidinas para el tratamiento de enfermedades inflamatorias |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US7511045B2 (es) |
| EP (2) | EP2060575A1 (es) |
| JP (1) | JP5021624B2 (es) |
| KR (1) | KR101335964B1 (es) |
| CN (1) | CN101163706A (es) |
| AR (1) | AR053235A1 (es) |
| AT (1) | ATE434620T1 (es) |
| AU (1) | AU2006237354B2 (es) |
| BR (1) | BRPI0608387A2 (es) |
| CA (1) | CA2605161A1 (es) |
| CY (1) | CY1109348T1 (es) |
| DE (2) | DE102005019201A1 (es) |
| DK (1) | DK1874781T3 (es) |
| EA (1) | EA013108B1 (es) |
| ES (1) | ES2328400T3 (es) |
| HR (1) | HRP20090395T1 (es) |
| IL (1) | IL186749A (es) |
| MX (1) | MX2007012313A (es) |
| NO (1) | NO20074615L (es) |
| NZ (1) | NZ563488A (es) |
| PL (1) | PL1874781T3 (es) |
| PT (1) | PT1874781E (es) |
| RS (1) | RS51163B (es) |
| SI (1) | SI1874781T1 (es) |
| TW (1) | TWI380984B (es) |
| UA (1) | UA93872C2 (es) |
| WO (1) | WO2006111549A1 (es) |
| ZA (1) | ZA200707591B (es) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8114878B2 (en) * | 2006-04-19 | 2012-02-14 | Boehringer Ingelheim International Gmbh | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases |
| US8637519B2 (en) | 2007-10-19 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Heterocycle-substituted piperazino-dihydrothienopyrimidines |
| US8754073B2 (en) | 2007-10-19 | 2014-06-17 | Boehringer Ingelheim International Gmbh | Substituted piperazino-dihydrothienopyrimidines |
| US9090626B2 (en) | 2007-10-19 | 2015-07-28 | Boehringer Ingelheim International Gmbh | Piperazino-dihydrothienopyrimidine derivatives |
| US9150586B2 (en) | 2011-08-24 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
| US10745411B2 (en) | 2011-08-24 | 2020-08-18 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8927546B2 (en) | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
| ES2462240T3 (es) | 2006-02-28 | 2014-05-22 | Dart Neuroscience (Cayman) Ltd | Piperazinas terapéuticas como inhibidores de PDE4 |
| PL1874781T3 (pl) | 2006-04-19 | 2009-12-31 | Boehringer Ingelheim Int | Dihydrotienopirymidyny do leczenia chorób zapalnych |
| CA2702500A1 (en) | 2007-10-18 | 2009-04-23 | Boehringer Ingelheim International Gmbh | Preparation of dihydrothieno [3, 2-d] pyrimidines and intermediates used therein |
| WO2009053268A1 (de) * | 2007-10-19 | 2009-04-30 | Boehringer Ingelheim International Gmbh | Neue phenyl-substituierte piperazino-dihydrothienopyrimidine |
| BRPI0821141A2 (pt) * | 2007-12-21 | 2015-06-16 | Hoffmann La Roche | Derivados de heteroarila como antagonistas do receptor de orexina |
| ES2375919T3 (es) | 2008-01-11 | 2012-03-07 | F. Hoffmann-La Roche Ag | Moduladores de beta-amiloide. |
| BRPI0907577A2 (pt) | 2008-02-22 | 2015-07-21 | Hoffmann La Roche | Moduladores para amiloide beta |
| AU2009246686B2 (en) * | 2008-05-13 | 2014-02-13 | Boehringer Ingelheim International Gmbh | Synthesis of dihydrothieno[3,2-d] pyrimidine diols and similar pyrimidine diols |
| JP5502089B2 (ja) | 2008-10-09 | 2014-05-28 | エフ．ホフマン−ラ ロシュ アーゲー | アミロイドβのモジュレーター |
| CN102209537A (zh) | 2008-11-10 | 2011-10-05 | 弗·哈夫曼-拉罗切有限公司 | 杂环γ分泌酶调节剂 |
| WO2010072631A1 (en) | 2008-12-24 | 2010-07-01 | Syngenta Limited | Methods for the preparation of fungicides |
| WO2010097334A1 (de) * | 2009-02-27 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids |
| WO2010097332A1 (de) * | 2009-02-27 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids |
| MA33159B1 (fr) * | 2009-03-10 | 2012-03-01 | Takeda Pharmaceutical | Derives de la coumarone |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| US20140113877A1 (en) * | 2011-06-15 | 2014-04-24 | Takeda Gmbh | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds |
| US9090624B2 (en) | 2011-08-04 | 2015-07-28 | Allergan, Inc. | Aromatic bycyclic derivatives as CXCR4 receptor modulators |
| US9206195B2 (en) | 2011-08-09 | 2015-12-08 | Boehringer Ingelheim International Gmbh | Dihydrothienopyrimidines |
| GB201203266D0 (en) * | 2012-02-24 | 2012-04-11 | Randox Lab Ltd | Assay for the detection of the phenylpiperazine family |
| US9422267B2 (en) | 2012-12-26 | 2016-08-23 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
| WO2014117947A1 (en) * | 2013-02-04 | 2014-08-07 | Grünenthal GmbH | 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors |
| WO2014124860A1 (en) | 2013-02-14 | 2014-08-21 | Boehringer Ingelheim International Gmbh | Specific pde4b-inhibitors for the treatment of diabetes mellitus |
| SG11201504709PA (en) | 2013-03-14 | 2015-07-30 | Dart Neuroscience Llc | Substituted pyridine and pyrazine compounds as pde4 inhibitors |
| CN104140426B (zh) * | 2013-05-07 | 2017-02-01 | 上海汇伦生命科技有限公司 | 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途 |
| CN103893183B (zh) * | 2014-03-12 | 2016-02-10 | 中山大学 | 1-（2-氯苯基）-4-{噻吩并[3,2-d]嘧啶-4-基}哌嗪化合物在制备抗HIV-1病毒药物中应用 |
| JP2018509377A (ja) * | 2014-12-05 | 2018-04-05 | サウザーン リサーチ インスチチュート | 生体アミン輸送モジュレータとしてのヘテロ環式化合物 |
| WO2019045824A1 (en) * | 2017-09-01 | 2019-03-07 | Kadmon Corporation, Llc | ALPHA PROPELLER PROTEIN KINASE INHIBITORS ("COILED-COIL") ASSOCIATED WITH RHO |
| CN111108109A (zh) | 2017-09-20 | 2020-05-05 | 利奥制药有限公司 | 取代的二氢噻吩并嘧啶及其作为磷酸二酯酶抑制剂的用途 |
| IL309150A (en) | 2017-10-23 | 2024-02-01 | Boehringer Ingelheim Int | A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases |
| EP3724194B1 (en) | 2017-12-15 | 2023-12-27 | UNION therapeutics A/S | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors |
| CN111712503B (zh) | 2017-12-15 | 2024-04-09 | 联合疗法公司 | 取代的四氢吡喃二氢噻吩并嘧啶类化合物及其作为磷酸二酯酶抑制剂的用途 |
| JP7203846B2 (ja) | 2017-12-15 | 2023-01-13 | ユニオン・セラピューティクス・アクティエセルスカブ | 置換アゼチジンジヒドロチエノピリジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用 |
| CN111285882B (zh) * | 2018-12-07 | 2022-12-02 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物、包含其的药物组合物及其制备方法和用途 |
| CN113248518B (zh) * | 2021-06-21 | 2022-03-25 | 山东大学 | 嘧啶哌嗪类衍生物及其制备方法与应用 |
| WO2023104958A1 (en) | 2021-12-09 | 2023-06-15 | Boehringer Ingelheim International Gmbh | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases |
| WO2023104961A1 (en) | 2021-12-09 | 2023-06-15 | Boehringer Ingelheim International Gmbh | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases |
| WO2024032673A1 (zh) * | 2022-08-09 | 2024-02-15 | 西藏海思科制药有限公司 | Pde4b抑制剂及其用途 |
| WO2024068386A1 (en) | 2022-09-28 | 2024-04-04 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor |
| WO2024067660A1 (zh) * | 2022-09-29 | 2024-04-04 | 苏州爱科百发生物医药技术有限公司 | 氮杂稠环类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1470336A1 (de) | 1962-07-04 | 1969-03-20 | Thomae Gmbh Dr K | Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung |
| NL124131C (es) * | 1963-06-17 | |||
| DE1470356A1 (de) * | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| NL123139C (es) | 1965-03-31 | |||
| BE754606A (fr) * | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
| DE2032687A1 (en) * | 1970-07-02 | 1972-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa |
| DE1940572A1 (de) * | 1969-08-08 | 1971-02-11 | Thomae Gmbh Dr K | Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| US3763156A (en) * | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
| FR2082496A5 (es) | 1970-03-18 | 1971-12-10 | Westinghouse Freins & Signaux | |
| RO62428A (fr) * | 1971-05-04 | 1978-01-15 | Thomae Gmbh Dr K | Procede pour la preparation des thyeno-(3,2-d)-pyrimidines |
| DE2121950A1 (en) * | 1971-05-04 | 1972-11-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity |
| DE2750288A1 (de) * | 1977-11-10 | 1979-05-17 | Thomae Gmbh Dr K | Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| US4256737A (en) | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
| US4265738A (en) * | 1979-10-25 | 1981-05-05 | Goncharov Evgeny S | Cleaning and/or grading machine for free-flowing materials |
| US5187168A (en) * | 1991-10-24 | 1993-02-16 | American Home Products Corporation | Substituted quinazolines as angiotensin II antagonists |
| JPH07330777A (ja) * | 1994-06-08 | 1995-12-19 | Taisho Pharmaceut Co Ltd | チエノ［３，２−ｄ］ピリミジン−４−オン誘導体 |
| US6339089B2 (en) * | 1997-08-13 | 2002-01-15 | Fujirebio Inc. | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same |
| NZ525733A (en) | 2000-10-12 | 2005-01-28 | Boehringer Ingelheim Pharma | Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament |
| DE10064994A1 (de) | 2000-12-23 | 2002-07-04 | Merck Patent Gmbh | Sulfamidothienopyrimidine |
| IL159238A0 (en) | 2001-06-22 | 2004-06-01 | Boehringer Ingelheim Pharma | Crystalline anticholinergic, method for its production, and use thereof in the production of a drug |
| US6587548B2 (en) | 2001-07-17 | 2003-07-01 | Hewlett-Packard Development Co., L.P. | Method and system of using a single telephone number for multiple services |
| WO2003055890A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| ES2305435T3 (es) * | 2002-01-10 | 2008-11-01 | Bayer Healthcare Ag | Inhibidores de la rho-quinasa. |
| EP1620437B1 (en) * | 2003-04-29 | 2009-06-17 | Pfizer Limited | 5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension |
| MY141220A (en) * | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| WO2005082865A1 (ja) * | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| PL1874781T3 (pl) | 2006-04-19 | 2009-12-31 | Boehringer Ingelheim Int | Dihydrotienopirymidyny do leczenia chorób zapalnych |
-
2006
- 2006-04-19 PL PL06743350T patent/PL1874781T3/pl unknown
- 2006-04-19 MX MX2007012313A patent/MX2007012313A/es active IP Right Grant
- 2006-04-19 UA UAA200712658A patent/UA93872C2/ru unknown
- 2006-04-19 EA EA200702200A patent/EA013108B1/ru not_active IP Right Cessation
- 2006-04-19 AT AT06743350T patent/ATE434620T1/de active
- 2006-04-19 DE DE102005019201A patent/DE102005019201A1/de not_active Withdrawn
- 2006-04-19 PT PT06743350T patent/PT1874781E/pt unknown
- 2006-04-19 SI SI200630405T patent/SI1874781T1/sl unknown
- 2006-04-19 RS RSP-2009/0333A patent/RS51163B/sr unknown
- 2006-04-19 CN CNA2006800134419A patent/CN101163706A/zh active Pending
- 2006-04-19 ES ES06743350T patent/ES2328400T3/es active Active
- 2006-04-19 JP JP2008507076A patent/JP5021624B2/ja active Active
- 2006-04-19 KR KR1020077027125A patent/KR101335964B1/ko not_active IP Right Cessation
- 2006-04-19 EP EP09152706A patent/EP2060575A1/de not_active Withdrawn
- 2006-04-19 AU AU2006237354A patent/AU2006237354B2/en not_active Ceased
- 2006-04-19 CA CA002605161A patent/CA2605161A1/en not_active Abandoned
- 2006-04-19 BR BRPI0608387-0A patent/BRPI0608387A2/pt not_active IP Right Cessation
- 2006-04-19 DK DK06743350T patent/DK1874781T3/da active
- 2006-04-19 EP EP06743350A patent/EP1874781B9/de active Active
- 2006-04-19 NZ NZ563488A patent/NZ563488A/en not_active IP Right Cessation
- 2006-04-19 DE DE502006004066T patent/DE502006004066D1/de active Active
- 2006-04-19 WO PCT/EP2006/061680 patent/WO2006111549A1/de active Application Filing
- 2006-04-20 TW TW095114162A patent/TWI380984B/zh not_active IP Right Cessation
- 2006-04-20 US US11/408,122 patent/US7511045B2/en active Active
- 2006-04-21 AR ARP060101573A patent/AR053235A1/es not_active Application Discontinuation
-
2007
- 2007-09-04 ZA ZA200707591A patent/ZA200707591B/xx unknown
- 2007-09-12 NO NO20074615A patent/NO20074615L/no not_active Application Discontinuation
- 2007-10-18 IL IL186749A patent/IL186749A/en not_active IP Right Cessation
-
2009
- 2009-02-19 US US12/388,835 patent/US7723341B2/en active Active
- 2009-07-10 HR HR20090395T patent/HRP20090395T1/hr unknown
- 2009-09-10 CY CY20091100939T patent/CY1109348T1/el unknown
-
2010
- 2010-04-02 US US12/753,477 patent/US8354531B2/en active Active
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8114878B2 (en) * | 2006-04-19 | 2012-02-14 | Boehringer Ingelheim International Gmbh | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases |
| US8604039B2 (en) | 2006-04-19 | 2013-12-10 | Boehringer Ingelheim International Gmbh | Dihydrothienopyrimidines for the treatment of inflammatory diseases |
| US8822474B2 (en) | 2006-04-19 | 2014-09-02 | Boehringer Ingelheim International Gmbh | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases |
| US8637519B2 (en) | 2007-10-19 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Heterocycle-substituted piperazino-dihydrothienopyrimidines |
| US8754073B2 (en) | 2007-10-19 | 2014-06-17 | Boehringer Ingelheim International Gmbh | Substituted piperazino-dihydrothienopyrimidines |
| US9090626B2 (en) | 2007-10-19 | 2015-07-28 | Boehringer Ingelheim International Gmbh | Piperazino-dihydrothienopyrimidine derivatives |
| US9115142B2 (en) | 2007-10-19 | 2015-08-25 | Boehringer Ingelheim International Gmbh | Heterocycle-substituted piperazino-dihydrothienopyrimidines |
| US9150586B2 (en) | 2011-08-24 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
| US10745411B2 (en) | 2011-08-24 | 2020-08-18 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053235A1 (es) | Derivados de tienopirimidinas para el tratamiento de enfermedades inflamatorias | |
| AR072657A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR070535A1 (es) | Compuestos inhibidores de raf y metodos para usarlos | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR081075A1 (es) | Derivados de imidazo[1,2-c]pirimidina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias. | |
| PE20200388A1 (es) | Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock | |
| AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
| AR075717A1 (es) | Compuestos de 3- aril quinazolin -4- ona para combatir plagas de invertebrados | |
| PE20160044A1 (es) | Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos | |
| AR082768A1 (es) | Derivados de indolizina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| CO6541645A2 (es) | Compuestos de indol y su uso farmaceutico | |
| CO6220934A2 (es) | Derivados de imidazolidinacaboxamida como inhibidores de lipasas y foffolipasas | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| AR076236A1 (es) | Compuestos organicos y sus usos | |
| AR060516A1 (es) | Dihidrotienopirimidinas utilizables en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de pde4 y composiciones farmaceuticas que las contienen. | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| ECSP088731A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| AR070264A1 (es) | Derivados de oxazepinopirimidona heteroarilamida sustituidos | |
| ECSP099216A (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR072819A1 (es) | Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
| AR077510A1 (es) | Derivados de dihidroindolonas, su procedimiento de preparacion y las com-posiciones farmaceuticas que los contienen | |
| AR050153A1 (es) | Beta-agonistas, procedimiento para su preparacion y su uso como medicamentos | |
| CL2022000551A1 (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |